Morgan Stanley has initiated Celldex Therapeutics (NASDAQ:CLDX) at overweight saying that barzolvolimab (barzol), its asset ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

Assessment of her symptoms showed her Urticaria Activity Score over 7 consecutive days (UAS 7) was 35 per week. In September of that year, she was taken off hydroxyzine due to the side effect of ...

Remibrutinib results in significant improvement in patients still symptomatic after second-generation H1-antihistamine treatment.

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral ...

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

Unlike allergic hives, chronic spontaneous urticaria (CSU) stems from immune system dysregulation and can persist for months or years, requiring ongoing management. Patients should understand that ...

Morgan Stanley initiated coverage of Celldex (CLDX) with an Overweight rating and $46 price target Celldex is developing antibodies for ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...